SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.
- HER-2 expression in biopsy and surgical specimen on prognosis of osteosarcoma: A systematic review and meta-analysis of 16 studies.Medicine · 2016Pooled it
- Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis.Oncotarget · 2015Pooled it
- Paediatric therapeutic development workshop on osteosarcoma.British journal of cancer · 2026Review
- Chromoanagenesis in Osteosarcoma.Biomolecules · 2025Review
- Isolation and Characterization of Novel Canine Osteosarcoma Cell Lines from Chemotherapy-Naïve Patients.Cells · 2023Article
- Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.International journal of molecular sciences · 2020Review
- Clinicopathological value of ErbB2 gene and protein expression in osteochondroma.Acta orthopaedica et traumatologica turcica · 2020Article
- Deciphering signaling networks in osteosarcoma pathobiology.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Question about Liu Y et al. entitled "Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies".Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- HER2 expression in gastric and oesophageal cancer: a meta-analytic review.Journal of gastrointestinal oncology · 2015Article
- Comments on Liu Yet al. "Effect of c-erbB2 overexpression on prognosis in osteosarcoma: evidence from eight studies".Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Single nucleotide polymorphisms of HER2 related to osteosarcoma susceptibility.International journal of clinical and experimental pathology · 2015Article
- Translational biology of osteosarcoma.Nature reviews. Cancer · 2014Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
C-erbB2 (HER-2/neu) plays an important role in the progression of several types of cancer by increasing tumor growth, migration, invasion, and metastasis and is associated with poor disease prognosis. Numerous studies examining the relationship between c-erbB2 expression and prognostic impact in patients with osteosarcoma have yielded inconclusive results. We therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic role of c-erbB2 expression on 5-year survival, which compared the positive and negative expression of c-erbB2 in patients of the available studies. A detailed search was made in PubMed for relevant original articles published in English. Finally, a total of eight studies with 411 osteosarcoma patients were involved to estimate the relationship between c-erbB2 expression and 5-year overall survival. Positive expressions of c-erbB2 predicted poorer survival in osteosarcoma with the pooled RR of 1.53 (95 % CI 1.20-1.94, P = 0.0006). In conclusion, the findings from this present meta-analysis suggest that c-erbB2 overexpression is related to poor prognostic of osteosarcoma and can be a useful clinical prognostic factor for those patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.